Get started
Author

Michele N. Mueller

Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
1999 · Dean J Kereiakes, Thomas M Broderick, et al. · The American Journal of Cardiology · 131
The ultegra rapid platelet-function assay: Comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy
2002 · Guy L. Wheeler, Gregory A. Braden, et al. · American Heart Journal · 52
Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab
2001 · Mark I. Furman, Dean J. Kereiakes, et al. · American Heart Journal · 48
First Human Use of RUC‐4: A Nonactivating Second‐Generation Small‐Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point‐of‐Care Treatment of ST‐Segment–Elevation Myocardial Infarction
2020 · Dean J. Kereiakes, Tim D. Henry, et al. · Journal of the American Heart Association · 47
Efficacy of Abciximab Induced Platelet Blockade Using a Rapid Point of Care Assay
1999 · Dean J. Kereiakes, Michele Mueller, et al. · Journal of Thrombosis and Thrombolysis · 40
High Platelet Count in Platelet-Rich Plasma Reduces Measured Platelet Inhibition by Abciximab but not Tirofiban nor Eptifibatide Glycoprotein IIb/IIIa Receptor Antagonists
2000 · Dean J. Kereiakes, Thomas M. Broderick, et al. · Journal of Thrombosis and Thrombolysis · 12
Quantification of abciximab-induced platelet inhibition is assay dependent: A comparative study in patients undergoing percutaneous coronary intervention
2003 · Mark I. Furman, Dean J. Kereiakes, et al. · American Heart Journal · 8
Works count: 7
Citation count: 338
H-index: 7
I10-index: 6
Year
Topic
Type